IP Library › Assignment 054999/0218
Patent Assignment
Reel/Frame 054999/0218

Assignment of Assignor's Interest

Recorded: 2021-01-14 Pages: 109
Assignor
PORTOLA PHARMACEUTICALS, LLC
Executed: 2020-11-05
Assignee
ALEXION PHARMACEUTICALS, INC.
121 SEAPORT BOULEVARD, BOSTON, MASSACHUSETTS, 02210
Covered Properties (107)
Methods of Treatment with Syk Inhibitors
Protein Kinase Inhibitors
Inhibitors of Syk Protein Kinase
Inhibitors of Protein Kinases
Inhibitors of Protein Kinases
Combination Therapy with 4-(3-(2H-1,2,3-Triazol-2-Yl)Phenylamino)-2-((1R,2S)-2-Aminocyclohexylamino)Pyrimidine-5-Carboxamide
Combination Therapy of 4-(3-(2H-1,2,3-Triazo-2-Yl)Phenylamino)-2-((1R,2S)-2-Aminocyclohexylamino)Pyrimidine-5-Carboxamide and Fludarabine
Combination Therapy of 4-(Cyclopropylamino)-2-(4-(4-(Ethylsulfonyl)Piperazin-1-Yl)Phenylamino)Pyrimidine-5-Carboxamide and Fludarabine
Oxypyrimidines as Syk Modulators
Benzamides and Nicotinamides as Syk Modulators
Pyrazine Kinase Inhibitors
Selective Kinase Inhibitors
Bicyclic Dihydropyridone Kinase Inhibitors
Bicyclic Oxa-Lactam Kinase Inhibitors
Substituted Picolinamide Kinase Inhibitors
1,2,4-Triazine-6-Carboxamide Kinase Inhibitors
Substituted Pyrimidinyl Kinase Inhibitors
Cyclohexanediamine Compounds and Methods for Their Preparation
Cerdulatinib for the Treatment of B-Cell Malignancies
Cerdulatinib for Treating Myeloma
Cerdulatinib for Treating Hematological Cancers
Methods of Use and Pharmaceutical Compositions of a Selective Syk Inhibitor
Synthesis of Cerdulatinib
Methods for Treating Lymphoma
Solid Forms of Cerdulatinib
Methods of Treatment with Syk Inhibitors
Patent: 8,057,815 →
Application: 11/107,324 →
Publication: US 2005/0232969
Protein Kinase Inhibitors
Patent: 7,705,004 →
Application: 12/192,034 →
Publication: US 2009/0054425
Inhibitors of Protein Kinases
Patent: 8,138,339 →
Application: 12/386,509 →
Publication: US 2009/0318407
Inhibitors of Syk and Jak Protein Kinases
Patent: 8,063,058 →
Application: 12/386,525 →
Publication: US 2010/0048567
Inhibitors of Protein Kinases
Patent: 8,258,144 →
Application: 12/386,848 →
Publication: US 2009/0298823
Methods of Treatment with Syk Inhibitors
Patent: 8,470,357 →
Application: 13/253,899 →
Publication: US 2012/0027834
Inhibitors of Syk and Jak Protein Kinases
Patent: 8,318,755 →
Application: 13/269,523 →
Publication: US 2012/0130073
Inhibitors of Syk and Jak Protein Kinases
Patent: 8,349,860 →
Application: 13/275,253 →
Publication: US 2012/0101275
Benzamides and Nicotinamides as Syk Modulators
Patent: 8,846,928 →
Application: 13/287,005 →
Publication: US 2012/0142671
Inhibitors of Protein Kinases
Patent: 8,501,944 →
Application: 13/360,862 →
Publication: US 2012/0129867
Inhibitors of Protein Kinases
Patent: 9,139,581 →
Application: 13/528,709 →
Publication: US 2013/0029944
Inhibitors of Syk and Jak Protein Kinases
Patent: 8,952,027 →
Application: 13/658,730 →
Publication: US 2013/0165431
Substituted Pyrazine-2-Carboxamide Kinase Inhibitors
Patent: 8,877,760 →
Application: 13/684,462 →
Publication: US 2013/0131040
Combination Therapy with 4-(3-(2H-1,2,3-Triazol-2-Yl)Phenylamino)-2-((1R,2S)-2-Aminocyclohexylamino)Pyrimidine-5-Carboxamide
Application: 13/823,699 →
Publication: US 2013/0244963
Combination Therapy of 4-(3-(2H-1,2,3-Triazo-2-Yl)Phenylamino)-2-((1R,2S)-2-Aminocyclohexylamino)Pyrimidine-5-Carboxamide and Fludarabine
Application: 13/823,710 →
Publication: US 2013/0252917
Combination Therapy of 4-(Cyclopropylamino)-2-(4-(4-(Ethylsulfonyl)Piperazin-1-Yl)Phenylamino)Pyrimidine-5-Carboxamide and Fludarabine
Application: 13/823,714 →
Publication: US 2013/0237493
1,2,4-Triazine-6-Carboxamide Kinase Inhibitors
Patent: 9,040,530 →
Application: 13/841,472 →
Publication: US 2013/0345191
Substituted Picolinamide Kinase Inhibitors
Application: 13/841,867 →
Publication: US 2014/0113931
Oxypyrimidines as Syk Modulators
Application: 13/882,958 →
Publication: US 2013/0317029
Inhibitors of Protein Kinases
Patent: 8,937,070 →
Application: 13/916,926 →
Publication: US 2014/0031361
Pyrazine Kinase Inhibitors
Patent: 9,359,308 →
Application: 14/360,178 →
Publication: US 2014/0309209
Selective Kinase Inhibitors
Application: 14/360,203 →
Publication: US 2014/0323418
Bicyclic Dihydropyridone Kinase Inhibitors
Patent: 9,533,986 →
Application: 14/432,146 →
Publication: US 2015/0266871
Bicyclic Oxa-Lactam Kinase Inhibitors
Patent: 9,469,654 →
Application: 14/432,162 →
Publication: US 2015/0252056
Substituted Pyrimidinyl Kinase Inhibitors
Patent: 9,676,756 →
Application: 14/434,075 →
Publication: US 2015/0259328
Benzamides and Nicotinamides as Syk Modulators
Patent: 9,359,375 →
Application: 14/458,163 →
Publication: US 2015/0038492
Inhibitors of Protein Kinases
Patent: 9,868,729 →
Application: 14/561,821 →
Publication: US 2015/0094298
Inhibitors of Syk and Jak Protein Kinases
Patent: 9,579,320 →
Application: 14/576,707 →
Publication: US 2015/0297595
Cyclohexanediamine Compounds and Methods for Their Preparation
Application: 14/771,768 →
Publication: US 2016/0009694
Benzamides and Nicotinamides as Syk Modulators
Patent: 9,902,688 →
Application: 15/151,413 →
Publication: US 2016/0318852
Cerdulatinib for Treating Myeloma
Application: 15/235,972 →
Publication: US 2017/0042896
Cerdulatinib for the Treatment of B-Cell Malignancies
Application: 15/578,190 →
Publication: US 2018/0147203
Cerdulatinib for Treating Hematological Cancers
Application: 15/780,414 →
Publication: US 2018/0353506
Inhibitors of Protein Kinases
Application: 15/828,154 →
Publication: US 2018/0186783
Synthesis of Cerdulatinib
Application: 16/402,880 →
Publication: US 2019/0337930
Methods for Treating Lymphoma
Application: 16/403,227 →
Publication: US 2020/0061060
Inhibitors of Protein Kinases
Application: 16/696,175 →
Publication: US 2020/0239458
Cerdulatinib for Treating Myeloma
Application: 16/831,471 →
Publication: US 2020/0222403
Cerdulatinib for Treating Hematological Cancers
Application: 16/931,038 →
Publication: US 2021/0000827
Methods of Use and Pharmaceutical Compositions of a Selective Syk Inhibitor
Application: 16/979,075 →
Publication: US 2021/0052582
Synthesis of Cerdulatinib
Application: 17/076,356 →
Publication: US 2021/0147392
Solid Forms of Cerdulatinib
Application: 17/098,852 →
Publication: US 2021/0130330
Methods of treatment with Syk inhibitors
Application: 60/563,710 →
Syk Inhibitors
Application: 60/956,643 →
Inhibitors of Protein Kinases
Application: 61/045,399 →
Inhibitors of Protein Kinases
Application: 61/045,406 →
Inhibitors of Protein Kinases
Application: 61/045,417 →
Inhibitors of Protein Kinases
Application: 61/045,499 →
Inhibitors of Protein Kinases
Application: 61/047,077 →
Inhibitors of Protein Kinases
Application: 61/120,341 →
Inhibitors of Protein Kinases
Application: 61/120,344 →
Inhibitors of Protein Kinases
Application: 61/120,346 →
Inhibitors of Protein Kinases
Application: 61/120,348 →
Combination Therapy with Inhibitors of Syk or Jak Protein Kinase
Application: 61/388,568 →
Combination Therapy of Inhibitor of Syk Protein Kinase and Fludarabine
Application: 61/388,570 →
Oxypyrimidines as Syk Modulators
Application: 61/409,060 →
Benzamides and Nicotinamides as Syk Modulators
Application: 61/409,077 →
Combination Therapy of Inhibitor of Syk Protein Kinase and Fludarabine
Application: 61/419,728 →
Selective Kinase Inhibitors
Application: 61/563,458 →
Pyrazine Kinase Inhibitors
Application: 61/563,466 →
1,2,4-Triazine-6-Carboxamide Kinase Inhibitors
Application: 61/663,499 →
Substituted Picolinamide Kinase Inhibitors
Application: 61/663,510 →
Bicyclic Dihydropyridone Kinase Inhibitors
Application: 61/706,681 →
Bicyclic Oxa-Lactam Kinase Inhibitors
Application: 61/706,712 →
Substituted Pyrimidinyl Kinase Inhibitors
Application: 61/711,170 →
Cyclohexanediamine Compounds and Methods for Their Preparation
Application: 61/792,318 →
Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates a Favorable Safety Profile and Evidence for Clinical Activity in Patients with Relapsed/Refractory B Cell Malignancies
Application: 62/168,530 →
Cerdulatinib for Treating of Multiple Myeloma
Application: 62/204,400 →
Cerdulatinib for Treating Hematological Cancers
Application: 62/263,582 →
Cerdulatinib for Treating of Multiple Myeloma
Application: 62/342,711 →
Cerdulatinib for Treating Hematological Cancers
Application: 62/342,727 →
Combinations with Cerdulatinib
Application: 62/342,755 →
Loss of IkappaBalpha Associated with Resistance to Cerdulatinib
Application: 62/371,145 →
Methods of Use and Pharmaceutical Compositions of a Selective Syk Inhibitor
Application: 62/641,094 →
Methods of Use and Pharmaceutical Compositions of a Selective Syk Inhibitor
Application: 62/663,999 →
Solid Forms of Cerdulatinib
Application: 62/667,226 →
Synthesis of Cerdulatinib
Application: 62/667,235 →
Methods for Treating Lymphoma
Application: 62/667,249 →
Methods for Treating Lymphoma
Application: 62/678,934 →
Methods for Treating Lymphoma
Application: 62/736,047 →
Synthesis of Cerdulatinib
Application: 62/822,714 →
Circulating B Cell Subpopulations in Indolent B Cell Lymphoma
Application: 63/030,095 →
Related Assignments (15)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest May 25, 2005
From: ANDRE, PATRICK; PHILIPS, DAVID R.; HOMCY, CHARLES
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 016596/0898 →
Assignment of Assignor's Interest Oct 27, 2008
From: SONG, YONGHONG; XU, QING; PANDEY, ANJALI
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 021740/0401 →
Assignment of Assignor's Interest Dec 10, 2009
From: BAUER, SHAWN M.; JIA, ZHAOZHONG J.; SONG, YONGHONG; XU, QING
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 023637/0058 →
Assignment of Assignor's Interest Dec 10, 2009
From: SONG, YONGHONG; XU, QING; BAUER, SHAWN M.; JIA, ZHAOZHONG J.
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 023637/0197 →
Assignment of Assignor's Interest Dec 29, 2009
From: JIA, ZHAOZHONG; VENKATARAMANI, CHANDRASEKAR; HUANG, WOLIN; MEHROTRA, MUKUND
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 023714/0299 →
Assignment of Assignor's Interest Dec 1, 2011
From: JIA, ZHAOZHONG J.; SONG, YONGHONG; XU, QING; KANE, BRIAN
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 027306/0892 →
Assignment of Assignor's Interest May 28, 2013
From: SINHA, UMA; PANDEY, ANJALI
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 030496/0585 →
Assignment of Assignor's Interest May 28, 2013
From: SINHA, UMA; PANDEY, ANJALI
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 030496/0291 →
Assignment of Assignor's Interest May 28, 2013
From: PANDEY, ANJALI; XU, QING; HUANG, WOLIN; JIA, ZHAOZHONG J.
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 030496/0411 →
Assignment of Assignor's Interest May 30, 2013
From: SINHA, UMA; PANDEY, ANJALI
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 030514/0352 →
Assignment of Assignor's Interest Apr 23, 2015
From: JIA, ZHAOZHONG; VENKATARAMANI, CHANDRASEKAR; HUANG, WOLIN; MEHROTRA, MUKUND
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 035481/0922 →
Assignment of Assignor's Interest Jun 15, 2018
From: PANDEY, ANJALI; COFFEY, GREGORY; LEEDS, JANET
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 046099/0573 →
Security Interest Mar 18, 2019
From: PORTOLA PHARMACEUTICALS, INC.
To: HCR COLLATERAL MANAGEMENT, LLC
Reel/Frame 048633/0673 →
Release of Security Interest Jul 2, 2020
From: HCR COLLATERAL MANAGEMENT, LLC
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 053120/0925 →
Change of Name Jan 12, 2021
From: PORTOLA PHARMACEUTICALS, INC.
To: PORTOLA PHARMACEUTICALS, LLC
Reel/Frame 054975/0183 →